{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:25:05Z","timestamp":1777267505127,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002992","name":"Department for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Directorate-General for International Cooperation"},{"name":"Ministry of Foreign and European Affairs"},{"DOI":"10.13039\/100009131","name":"Swiss Agency for Development and Cooperation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejmech.2020.112849","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T11:19:42Z","timestamp":1600427982000},"page":"112849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in\u00a0vitro and in\u00a0vivo trypanocidal efficacy"],"prefix":"10.1016","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-8559","authenticated-orcid":false,"given":"Andrew M.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick D.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-2001","authenticated-orcid":false,"given":"Andrew J.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3475-8130","authenticated-orcid":false,"given":"Amanda F.","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine J.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-5688","authenticated-orcid":false,"given":"Scott","family":"Cornwall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.C. Andrew","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-6949","authenticated-orcid":false,"given":"Karen L.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-8213","authenticated-orcid":false,"given":"Susan A.","family":"Charman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Zulfiqar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa L.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky M.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3158-7743","authenticated-orcid":false,"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7997-1843","authenticated-orcid":false,"given":"William A.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112849_bib1","unstructured":"World Health Organization, Chagas disease (also known as American trypanosomiasis), Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis) and https:\/\/www.who.int\/chagas\/epidemiology\/en\/(accessed 8 April, 2020).Crossref Partial Au1 ATL"},{"key":"10.1016\/j.ejmech.2020.112849_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1051\/parasite\/2014012","article-title":"Chagas disease in the 21st Century: a public health success or an emerging threat?","volume":"21","author":"Bonney","year":"2014","journal-title":"Parasite"},{"key":"10.1016\/j.ejmech.2020.112849_bib3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fpubh.2019.00166","article-title":"Chagas disease: from discovery to a worldwide health problem","volume":"7","author":"Lidani","year":"2019","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejmech.2020.112849_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: toward a new era","volume":"20","author":"Chatelain","year":"2015","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.ejmech.2020.112849_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1590\/0037-8682-0433-2016","article-title":"Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America","volume":"50","author":"Pinheiro","year":"2017","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.ejmech.2020.112849_bib6","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1017\/S0031182017001469","article-title":"Biological factors that impinge on Chagas disease drug development","volume":"144","author":"Francisco","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.ejmech.2020.112849_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2019.165628","article-title":"The unmet medical need for Trypanosoma cruzi-infected patients: monitoring the disease status","volume":"1866","author":"Zrein","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2020.112849_bib8","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112849_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/1087057116673796","article-title":"Evaluation of parameters impacting drug susceptibility in intracellular Trypanosoma cruzi assay protocols","volume":"22","author":"Yang","year":"2017","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.ejmech.2020.112849_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpddr.2016.08.003","article-title":"Assessing anti-T.\u00a0cruzi candidates in\u00a0vitro for sterile cidality","volume":"6","author":"Cal","year":"2016","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ejmech.2020.112849_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004584","article-title":"Identification of trypanocidal activity for known clinical compounds using a new Trypanosoma cruzi hit-discovery screening cascade","volume":"10","author":"De Rycker","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2020.112849_bib12","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00520-15","article-title":"Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in\u00a0vivo imaging","volume":"59","author":"Francisco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112849_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112849_bib14","doi-asserted-by":"crossref","first-page":"35351","DOI":"10.1038\/srep35351","article-title":"Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage","volume":"6","author":"Francisco","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112849_bib15","doi-asserted-by":"crossref","first-page":"e02515","DOI":"10.1128\/AAC.02515-18","article-title":"Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone marrow toxicities of the new trypanoside fexinidazole","volume":"63","author":"Watson","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112849_bib16","unstructured":"Drugs for Neglected Diseases initiative, Fexinidazole for Chagas, Available at: https:\/\/dndi.org\/research-development\/portfolio\/fexinidazole-for-chagas\/(accessed 30 August, 2020)."},{"key":"10.1016\/j.ejmech.2020.112849_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/QCO.0b013e32834c630e","article-title":"Boron-based drugs as antiprotozoals","volume":"24","author":"Jacobs","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112849_bib18","doi-asserted-by":"crossref","first-page":"10158","DOI":"10.1021\/jm401610c","article-title":"Two analogues of fenarimol show curative activity in an experimental model of Chagas disease","volume":"56","author":"Keenan","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02717-16","article-title":"Nitrotriazole-based compounds as antichagasic agents in a long-treatment in\u00a0vivo assay","volume":"61","author":"Papadopoulou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112849_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpddr.2019.11.004","article-title":"Current trends in the pharmacological management of Chagas disease","volume":"12","author":"Ribeiro","year":"2020","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ejmech.2020.112849_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17460441.2020.1681394","article-title":"Why hasn\u2019t there been more progress in new Chagas disease drug discovery?","volume":"15","author":"Vermelho","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112849_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112849_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/acsmedchemlett.8b00498","article-title":"Triazolopyrimidines and imidazopyridines: structure-activity relationships and in\u00a0vivo efficacy for trypanosomiasis","volume":"10","author":"Nagendar","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112849_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/tropicalmed5010028","article-title":"Anti-trypanosomal proteasome inhibitors cure hemolymphatic and meningoencephalic murine infection models of African trypanosomiasis","volume":"5","author":"Rao","year":"2020","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112849_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/17460441.2018.1417380","article-title":"Phenotypic screening approaches for Chagas disease drug discovery","volume":"13","author":"Chatelain","year":"2018","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112849_bib26","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.bmcl.2016.03.103","article-title":"Repuposing strategies for tropical disease drug discovery","volume":"26","author":"Klug","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112849_bib27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112849_bib30","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","article-title":"Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: structure\u2013activity studies on a preclinical candidate for visceral leishmaniasis","volume":"59","author":"Thompson","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib31","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/acs.jmedchem.7b00034","article-title":"7-Substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis","volume":"60","author":"Thompson","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib32","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1021\/jm2015809","article-title":"Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease","volume":"55","author":"Keenan","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/jm901207n","article-title":"Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Palmer","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1021\/jm801087e","article-title":"Synthesis, reduction potentials, and antitubercular activity of ring A\/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"52","author":"Thompson","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib35","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/j.bmcl.2017.03.069","article-title":"6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases","volume":"27","author":"Thompson","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112849_bib36","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1021\/jm200377r","article-title":"Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"54","author":"Thompson","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bmcl.2017.10.067","article-title":"Assessment of a pretomanid analogue library for African trypanosomiasis: hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides","volume":"28","author":"Thompson","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112849_bib38","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1016\/j.bmcl.2015.07.084","article-title":"Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: effects of proximal ring substitution and linker reversal on metabolism and efficacy","volume":"25","author":"Thompson","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112849_bib39","series-title":"Nitro-[2,1-b]imidazopyran Compounds and Antibacterial Uses Thereof","author":"Baker","year":"2000"},{"key":"10.1016\/j.ejmech.2020.112849_bib40","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1021\/jm101288t","article-title":"Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Kmentova","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib41","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1016\/j.bmc.2017.05.038","article-title":"An orthogonally protected CycloTriVeratrylene (CTV) as a highly pre-organized molecular scaffold for subsequent ligation of different cyclic peptides towards protein mimics","volume":"25","author":"Longin","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib42","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/104265090889404","article-title":"A\u00a0green protocol for the easy synthesis of thiiranes from epoxides using thiourea\/silica gel in the absence of solvent","volume":"180","author":"Iranpoor","year":"2005","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"key":"10.1016\/j.ejmech.2020.112849_bib43","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1021\/jo00240a017","article-title":"Regioselective opening of simple epoxides with diisopropylamine trihydrofluoride","volume":"53","author":"Muehlbacher","year":"1988","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib44","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis","volume":"57","author":"Patterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112849_bib45","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6R)-2-nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): a new lead for visceral leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004014","article-title":"Development of a fluorescence-based Trypanosoma cruzi CYP51 inhibition assay for effective compound triaging in drug discovery programmes for Chagas disease","volume":"9","author":"Riley","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2020.112849_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpddr.2015.10.001","article-title":"Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes","volume":"5","author":"Sykes","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ejmech.2020.112849_bib48","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.2174\/0929867325666180426164352","article-title":"Current and future prospects of nitro-compounds as drugs for trypanosomiasis and leishmaniasis","volume":"26","author":"Patterson","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112849_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2020.112849_bib50","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.00332-10","article-title":"Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis","volume":"54","author":"Sokolova","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112849_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112849_bib52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1087057114552623","article-title":"A\u00a0new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in\u00a0vivo imaging","volume":"20","author":"Lewis","year":"2015","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.ejmech.2020.112849_bib53","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1023\/A:1010927026837","article-title":"The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs","volume":"18","author":"Basit","year":"2001","journal-title":"Pharm. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:24:48Z","timestamp":1759328688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420308217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":51,"alternative-id":["S0223523420308217"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112849","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in\u00a0vitro and in\u00a0vivo trypanocidal efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112849"}}